The pharmaceutical industry is faced with steadily declining R&D efficiency which results in fewer drugs reaching the market despite increased investment. A major cause for this low efficiency is the failure of drug candidates in late-stage development owing to safety issues or previously undiscovered side-effects.
Introduction
In today's pharmaceutical industry, a relatively small number of drugs are being approved, whereas research expenses are increasing, patents are expiring and governments and health insurance companies are pushing for lowcost medications [1] . This situation is exacerbated by an average of 10% of marketed drugs being withdrawn from the market at some stage or requiring black box warnings because of adverse biological effects and failures in clinical Phase III and after. FDA submission failures have increased to 50% in recent years [2] . In addition to health risks for clinical trial participants, late failures are extremely costly because large amounts of time and capital have already been invested in developing the drug. Depending on the assumptions made, the development of a new drug costs in the order of US$1 billion and takes the best part of a decade to reach the market [3, 4] . Accordingly, the 'Holy Grail' of drug development is to identify future failures early -even before they enter clinical phases -and thereby save significant expenditures later on. In pharmaceutical drug discovery the correct go/no-go decisions must be made during all phases; however, decisions are particularly crucial during lead optimization, because they determine which compounds will enter costly preclinical and clinical development [5, 6] (Table 1) . These decisions should ideally be based on scientific parameters that are predictive of later outcomes and can be measured quickly and cost-effectively.
To make decisions on a scientific basis, researchers in the pharmaceutical industry are now using a range of technologies for measuring the biological effects of compounds. These technologies are generally related either to efficacy, such as early-stage measuring of compound-target interactions or animal-based readouts in later stages, or to the detection of adverse effects, such as safety profiling [7, 8] or more-complex biological readouts. The assays used can capture either single biological effects -the inhibition of a certain enzyme for instance -or multiple biological effects, such as mRNA-, protein-and imaging-based techniques [9] [10] [11] . In principle, the latter can take 'all' biological activities of a compound in a living system into account and provide data that convey more information about its properties [10] . A multidimensional assay that measured a wide diversity of biological effects during lead optimization would be highly desirable for making the right decisions exceptionally early in the drug development process and would save considerable amounts of time and money. However, the applicability of these biotechnologies for the evaluation of compound efficacy and safety in real drug development projects is still to be demonstrated. One of the multidimensional assays that has gained considerable attention in the past decade is gene expression profiling. This technique simultaneously measures many of the biological effects of a compound on the transcriptional level, and thereby gives a comprehensive snapshot of the biological state of a living system [12] [13] [14] . Transcriptomic changes following compound administration can now also be measured in high throughput, enabling screening of many compounds in multiple cell lines at low cost. The use of transcriptomic data for characterizing biological effects of small molecules has become increasingly popular since the advent of the Connectivity Map [15] . Several applications ranging from pathway elucidation [16] , toxicity models [17, 18] and toxicogenomic classifications [19] to tool discovery and drug repurposing [20] [21] [22] [23] have been developed based on drug-induced gene expression profiling [9] . However, whereas these studies certainly have significant scientific value, they do not address the utility of gene expression profiling for decision making during the lead optimization phase of a typical drug discovery project. The objective of this phase is first to prioritize a few chemotypes from previous phases and then to optimize these lead compounds into their desired bioactivity profiles as well as ADMETox properties. This is very different from the repurposing applications of Connectivity Map, in which compounds are selected from a library with broad functional and structural diversity. During lead optimization a very narrow chemical space is being considered, and more-fine-grained decisions need to be made. The studies cited above did not consider transcriptional profiles at the level of resolution required for their use in the lead optimization phase -a deficiency that our work aims to address.
Few findings have been published on how gene expression facilitates go/no-go decisions during lead optimization. In one example, Fanton et al. [24] found that gene expression data help in the optimization of closely chemically related compounds. However, this study focused solely on on-target effects, whereas in lead optimization the detection of off-target effects is crucial. Baum et al. [25] investigated off-target effects and were able to prioritize compounds based on transcriptional profiles; however, only a small number of compounds from a single project were considered. This is insufficient for assessing the utility of transcriptomic data for decision making in early-stage pharmaceutical drug discovery.
We have now evaluated the utility of gene expression profiling in eight drug discovery projects, named according to their biomolecular target: fibroblast growth factor receptor (FGFR), epidermal growth factor receptor (EGFR), ROS1, hepatitis B virus (HBV), mGluR2PAM, phosphodiesterase (PDE)10A, PDE4 and microsomal triglyceride transfer protein (MTP); across four disease areas: oncology, virology, neuroscience and metabolic diseases. The experiments were performed from 2010 to 2013 at Janssen Research and Development, as part of the Quantitative Structure Transcriptional Activity Relationships (QSTAR) Project [26] . We measured the transcriptional effects of 757 compounds on eight cell lines using a total of 1600 microarrays developed by Affymetrix. On the basis of these experiences, we found gene expression profiling to be a highly valuable tool for lead optimization in pharmaceutical discovery projects. Table 2 provides an overview of the projects and disease areas that were explored in this study with regard to the utility of using transcriptomic data (measured by microarrays) in the lead optimization phase of pharmaceutical drug discovery projects. Transcriptomic data provided relevant information for six of the eight projects. For three of them (ROS1, EGFR and PDE10A) the data provided clear go/no-go decisions. In three other projects (FGFR, mGluR2PAM and MTP) transcriptomics delivered novel biological insights but did not provide direct decision support. In the remaining two cases (HBV and PDE4) neither biological insights nor go/no-go decisions were gained. Four projects are 
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This list is incomplete, but it illustrates the large number of multidimensional choices to be made during a typical project, most of which are go/no-go decisions between either two or several (or even very many) options. In this work, we are particularly interested in supporting decisions in the lead optimization stage using gene expression data.
described in detail here. The remaining projects are described in Supplementary material.
PDE10A project
In this project, the aim was to develop compounds inhibiting PDE10A which is almost exclusively expressed in the striatum and is considered as a novel therapeutic avenue in the discovery of antipsychotics [27] . Although the efficacy of the investigated compounds was high, adverse effects emerged as a point of concern. Therefore, the compounds were profiled with respect to their induced gene expression on HEK293 cells transfected with the mouse homolog of PDE10A. Three compounds strongly downregulated the expression of tubulin genes (Fig. 1b) , which was the strongest transcriptional module observed ( Fig. 1c ) in this experiment. Downregulation of tubulin genes suggests a possible genotoxic effect on the microtubule-based chromosome segregation (Fig. 1a) . Hence the compounds were profiled in a micronucleus test (MNT) [28] -a genotoxicity test for detecting micronuclei in the cytoplasm of interphase cells. The micronuclei formation for one of the three compounds showing tubulin downregulation is presented in Fig. 1d . The tubulin downregulation was strongly correlated with highly positive MNT scores (a 20.6-fold to 28.1-fold increase in micronuclei formation). By contrast, structurally similar compounds with nonsignificant tubulin downregulation did not show an influence on micronucleus formation. The tubulin genes were used in a next step as a gene signature to query the Connectivity Map [15, 29] . The top five ranked compounds retrieved with this signature were mebendazole (two instances), chelidonine, vinblastine and nocodazole. Vinblastine is a known reference compound used in MNT assays as a positive control for the induction of MN formation [30] . Mebendazole and nocodazole are both benzimidazoles that are also considered model compounds for demonstrating thresholded responses of aneugenic compounds [31] . Hence, our identification of MNT-positive compounds using gene expression signatures could also be validated on external data. In a subsequent transcriptional profiling experiment, nocodazole was also profiled, and the link between tubulin genes and a positive MNT could be confirmed ( Fig. S1 in Supplementary material online).
The results from the PDE10A project clearly show that transcriptomic profiling can identify potentially genotoxic compounds in an early phase of drug development. This is of practical utility, given that in the standard drug discovery pipeline in vitro pharmacological profiling for the formation of micronuclei is usually applied at a rather late stage. The tubulin gene expression signature, however, allows identification of micronucleus formation much earlier and, thereby, prevents failure of selected compounds owing to this effect at later stages.
EGFR project
Our second project was an oncology project, focusing on inhibition of EGFR [32] . Given increasing resistance to current EGFR inhibitors (gefitinib and erlotinib) [33] , there is still a need for novel therapies. Compounds with a macrocycle structure were derived from the two reference compounds (Fig. 2c) and synthesized. Thirty-five of them were selected for transcriptomic profiling to identify compounds with similar biological effects to the reference compounds. A compound-induced transcriptional module was discovered (see supplementary material online) in which some genes were downregulated for the two reference compounds as well as five macrocycle compounds (Fig. 2a) . The most significant gene of this module encodes the fibroblast growth factor carrier protein (FGFBP1) the expression of which is downregulated via the mitogen-activated protein kinase/extracellular signal-related kinase (MAPK/ERK) pathway after EGF-stimulated inhibition of EGFR [34] . Also, several other genes of the module, such as FOSL1, are located downstream of the MAPK/ERK pathway [35] .
We confirmed that this transcriptional effect induced by the compounds and gefitinib and erlotinib is related to the inhibition of the proliferation of cancer cells by an assay measuring cell growth: FGFBP1 downregulation is indeed highly negatively correlated with the proliferation assay (Fig. 2c) . Additionally, we were able to link cell growth activity and FGFBP1 downregulation to a particular chemical feature (Fig. 2c,d) , which was detrimental to biological activity and, in turn, probably also to the efficacy of the compound. One of the five active macrocycles could be deprioritized based on a potential severe off-target effect discovered solely using transcriptomics data. In the case of this compound, mitochondrial membrane genes like MT1X were found to be downregulated, which might hint to a failure at later phases [36] (Fig. 2b) . This resulted in a clear no-go decision for further development for this compound. This example demonstrates the use of gene expression profiling as a tool to confirm the desired effect and to obtain insight into the mechanism of action. Because transcriptomics experiments allow the discovery of adverse effects, one of the active compounds could be additionally deprioritized based on a specific transcriptional effect.
MTP project
The goal of the project was to develop compounds that modulate MTP, which alters the cholesterol level [37, 38] via downregulation of the cholesterol biosynthesis pathway [39] . Ketoconazole, an antifungal agent that blocks cytochrome P450 14-alpha-demethylase (P450-14DM), has multiple biomolecular targets and is known to reduce cholesterol levels [40] . Structural derivatives of ketoconazole were synthesized as potential MTP inhibitors, although lead optimization of compounds with multiple unknown targets is challenging with traditional biochemical assays. Therefore, the compounds were profiled using gene expression on multiple cell lines: LnCap (human prostate cancer), HepG2 (human liver carcinoma) and SK-N-BE(2) (human brain cancer). A transcriptional module containing ten downregulated genes that belong to the sterol regulatory element binding protein (SREBP) cholesterol metabolism pathway was detected in LnCap and HepG2 cells (Fig. 3a,b) but not in SK-N-BE(2). Given the downregulation of these genes, we reasoned that the inhibition of MTP increases the cholesterol concentration in the endoplasmatic reticulum [41, 42] , which is detected by the SREBP cleavage activating protein (SCAP). Owing to the high level of cholesterol, SCAP cannot activate SREBP [43, 44] , and thus the cholesterol biosynthesis pathway is downregulated as desired. However, the ranking of the compounds based on the gene expression patterns of the SREBP pathway genes is different between the two cell lines (Fig. 3c) , and it only partially correlates with the cellular assays measuring MTP inhibition (see Supplementary material online). Owing to this inconsistency, other transcriptional modules were not further investigated. Although transcriptomic effects related to the expected metabolic pathway are observed in this project, further investigation and exploitation are required before a decision can be made; however, we did acquire biological insights into the mode of action of the compounds. TUBA1A   TUBA1C   TUBA4A   TUBA1B   TUBG1  TUBBP5   TUBB4   TUBB6   TUBB8   TUBB2C   TUBB2B   Positive MNT  aneugenic   TUBB2A   TUBB3  TUBB   TUBB   TUBB6   TUBG1   TUBA1A   TUBA1C   6  7  8  9  10  11  12   TUBB2B   TUBB2A   TUBBP5   TUBB4A   TUBB4B   TUBB3 Daughter cells with micronuclei 
ROS1 project
This project sought to develop compounds that inhibit the proto-oncogene tyrosine protein kinase ROS (ROS1). The ROS1 gene is overexpressed in several cancer types [45, 46] . Lack of selectivity was a particular concern given the historical precedent for compounds of this target class [47] . Five chemotypes (A-E) had been identified from the cellular screen for target inhibition. We used the number of gene expression changes induced by a given compound as a measure of the selectivity of that compound. This analysis clearly identified chemotype A as the most selective (i.e. least effects on gene expression; Fig. 4a ), which was selected for continued development. At the same time, nogo decisions were made on the other chemotypes (B-E).
In an attempt to improve the inhibitory activity of compounds of chemotype A, 100 analogs were synthesized. Cellular assays for target inhibition indeed identified compounds with high inhibitory activity among the analogs of chemotype A. Our gene expression analysis showed that there was no loss of the desirable selectivity for even the most active analogs. These drug candidates were thus promoted to further preclinical development (Fig. 4b) . This example demonstrates the use of gene expression profiling to complement a focused cellular assay during compound selection and the qualification of individual compounds for further optimization.
Discussion
Assessing the utility of transcriptomic data for decision making in early-stage pharmaceutical drug discovery is rather challenging. The drug discovery process spans a long time period, typically more than ten years. Hence, the impact of decisions made during the QSTAR project cannot be fully demonstrated because many projects are still ongoing. These limitations are inherently linked to such an assessment exercise. However, given the examples, it is shown that transcriptional profiling experiments can contribute to decision making during the lead optimization phase of drug discovery projects. The multidimensional data generated from transcriptomics experiments are 'richer' than conventional assays based on single readouts. They allow discovery of multiple patterns within the same experiment that relate to different characteristics of the compounds under investigation. Besides identifying interesting transcriptional effects, project-relevant information can also be gathered by quantifying the transcriptional changes on an absolute scale. A compound was defined as being 'selective' when the number of differentially expressed genes after compound administration is low compared with other compounds within the same project. Additionally, it is shown in the EGFR project that transcriptomics data can be integrated in more classical SAR modeling exercises. Although transcriptomics data have been shown to support decision making in a number of projects, they also have their limitations. Conceptually, transcriptional profiling is limited in its nature because it cannot detect changes at the metabolite or protein level. There could be compounds that affect the function of a pathway which is not reflected by a transcriptional change. In general, from the data presented in this work, higher numbers of transcriptional effects were observed in oncology projects. A plausible explanation is that the antiproliferative activity of these compounds typically affects many biological processes that are linked with transcriptional changes.
We are not yet at a stage where we can easily annotate the majority of transcriptional responses and have assays readily available to check the validity of each observation. As a consequence, we could create data on candidate drugs that are not yet interpretable but might prove beneficial in their ongoing development. This emphasizes the exploratory nature of transcriptomics experiments. It enables the generation of interesting hypotheses early but important decisions could require validation in follow-up experiments.
As with all cell-based assays, the amount of information that can be gained from transcriptomic profiling depends on the type of cell line. For detection of transcriptional effects related to the desired activity, cell lines expressing the target are suggested, whereas some adverse effects might only be observable in other cell lines. Besides cell line dependency, investigation of compound-induced effects can be heavily dose-and time-dependent. All compounds within a certain project are profiled in equimolar conditions to assess the differences in efficacy. However, when the potencies between the compounds within a project are diverse, some compounds are too dilute to show effects. These dependencies illustrate that an optimization of the parameters (cell line, concentration and administration time) before profiling is needed to maximize the information that can be gained from transcriptomic data. However, such an optimization is only affordable when gene expression profiling technologies become even less costly and more suitable for higher throughput like the L1000 platform [48] . In the other direction, high throughput RNA sequencing (RNA-Seq) enables more in-depth analysis of transcriptional changes at a higher cost. The transcriptomic data described in this paper were all generated using microarray gene expression chips, but the concepts, approaches and conclusions can be directly transferred to platforms such as L1000 and RNA-Seq [49] .
The overall conclusion of QSTAR is that transcriptomic data typically detect biologically relevant signals and are often able to help prioritize compounds beyond conventional target-based assays. Most value is added to the decision making process by warning signals that flag offtarget effects early on. Because gene expression profiling is nowadays an affordable and fast technique, in particular when compared with other assays, it has the potential to be included as a standard method early in the drug development process to detect such off-target effects. We expect that in the future the applicability of transcriptional profiling will increase further owing to continuous investments in the annotation of transcriptional responses.
Materials and methods
For each project, gene expression data were initially obtained for a small set of candidate compounds, reference compounds (e.g. FDAapproved drugs), target-active representatives of candidate chemotypes and controls in a cell system and at equimolar concentration and treatment duration recommended by the respective Janssen project teams. In some cases, the set of compounds was extended with structural analogs that were synthesized following certain decision points (see Supplementary material online). The mRNA expression data were quantile normalized, summarized [13] and filtered [50, 51] . Subsequent exploratory analysis to detect strong transcriptomic effects was performed using spectral map analysis [52] . Differentially expressed genes [53] were called and transcriptional modules [54] Chemotype selection in the ROS1 project: chemotypes A, B, C, D and E are shown in pink, brown, green, blue and purple, respectively. (a) Bar plot showing the number of genes with an absolute log fold change greater than 1 compared with the controls for each of the compounds in the initial set. The white spaces indicate compounds for which no genes had an absolute log fold change greater than 1. The compounds are ordered within a chemotype according to their inhibitory activity (represented by dots, expressed in pIC 50 ). Compounds of chemotype A show the least number of transcriptional effects, but also on average lower activity profiles. (b) Bar plot showing the number of genes with an absolute log fold change greater than 1 compared with the controls for each of the compounds in the extended compound set of the ROS1 project. Additional compounds in chemotype A were added. Compounds are ordered again based on pIC 50 within chemotypes.
by the factor analysis for bicluster acquisition (FABIA) method [55] . Transcriptional modules related to the desired effect were identified by the potential support vector machine (PSVM) using target-related bioassay measurements [56] . A data framework and analysis pipeline was constructed to facilitate integrated analysis of gene expression data, chemical structures and bioassay results (see Supplementary material online).
